Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T Cells following human-,simian-,and chimpanzee-derived recombinant adenoviral vector immunization

Journal of Immunology

Volumn 190, Issue 6, 2013, Pages 2720-2735

  Quinn, Kylie M ^a   Da Costa, Andreia ^a   Yamamoto, Ayako ^a   Berry, Dana ^a   Lindsay, Ross W B ^a   Darrah, Patricia A ^a   Wang, Lingshu ^a   Cheng, Cheng ^a   Kong, Wing Pui ^a   Gall, Jason G D ^b   Nicosia, Alfredo ^c,d,e   Folgori, Antonella ^c   Colloca, Stefano ^c   Cortese, Riccardo ^c,d   Gostick, Emma ^f   Price, David A ^f   Gomez, Carmen E ^g   Esteban, Mariano ^g   Wyatt, Linda S ^a   Moss, Bernard ^a   Morgan, Cecilia ^h   Roederer, Mario ^a   Bailer, Robert T ^a   Nabel, Gary J ^a   Koup, Richard A ^a   Seder, Robert A ^a   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GENVEC INC   (United States)

^c Okairos Srl ^*  (Italy)

^d CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^h USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE COFACTOR PROTEIN; RECOMBINANT VACCINE; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS INFECTION; ANIMAL CELL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHIMPANZEE; COLONY FORMING UNIT; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MALARIA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SEROLOGY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

ADENOVIRIDAE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, GAG; GENETIC VECTORS; HEK293 CELLS; HIV-1; HUMANS; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PAN TROGLODYTES; QUALITY ASSURANCE, HEALTH CARE; RECOMBINANT PROTEINS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84874860188     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202861     Document Type: Article

References (83)

1. Thaiss, C. A., and S. H. E. Kaufmann. 2010. Toward novel vaccines against tuberculosis: current hopes and obstacles. Yale J. Biol. Med. 83: 209-215
2. Spence, P. J., and J. Langhorne. 2012. T cell control of malaria pathogenesis. Curr. Opin. Immunol. 24: 444-448
3. Koup, R. A., J. T. Safrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655
4. Abbink, P., A. A. C. Lemckert, B. A. Ewald, D. M. Lynch, M. Denholtz, S. Smits, L. Holterman, I. Damen, R. Vogels, A. R. Thorner, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81: 4654-4663
5. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91
6. Catanzaro, A. T., R. A. Koup, M. Roederer, R. T. Bailer, M. E. Enama, Z. Moodie, L. Gu, J. E. Martin, L. Novik, B. K. Chakrabarti, et al; Vaccine Research Center 006 Study Team. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replicationdefective recombinant adenovirus vector. J. Infect. Dis. 194: 1638-1649
7. Priddy, F. H., D. Brown, J. Kublin, K. Monahan, D. P. Wright, J. Lalezari, S. Santiago, M. Marmor, M. Lally, R. M. Novak, et al; Merck V520-016 Study Group. 2008. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46: 1769-1781
8. Bassett, J. D., S. L. Swift, and J. L. Bramson. 2011. Optimizing vaccine-induced CD8+ T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev. Vaccines 10: 1307-1319
9. Abel, B., M. Tameris, N. Mansoor, S. Gelderbloem, J. Hughes, D. Abrahams, L. Makhethe, M. Erasmus, M. de Kock, L. van der Merwe, et al. 2010. The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. Am. J. Respir. Crit. Care Med. 181: 1407-1417
10. Sheehy, S. H., C. J. Duncan, S. C. Elias, K. A. Collins, K. J. Ewer, A. J. Spencer, A. R. Williams, F. D. Halstead, S. E. Moretz, K. Miura, et al. 2011. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol. Ther. 19: 2269-2276
11. Sheehy, S. H., C. J. A. Duncan, S. C. Elias, S. Biswas, K. A. Collins, G. A. O'Hara, F. D. Halstead, K. J. Ewer, T. Mahungu, A. J. Spencer, et al. 2012. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 7: e31208
12. Sedegah, M., C. Tamminga, S. McGrath, B. House, H. Ganeshan, J. Lejano, E. Abot, G. J. Banania, R. Sayo, F. Farooq, et al. 2011. Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: Safety and immunogenicity in seronegative adults. PLoS ONE 6: e24586
13. Tamminga, C., M. Sedegah, D. Regis, I. Chuang, J. E. Epstein, M. Spring, J. Mendoza-Silveiras, S. McGrath, S. Maiolatesi, S. Reyes, et al. 2011. Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: Safety, immunogenicity and protective efficacy of the CSP component. PLoS ONE 6: e25868
14. Barouch, D. H., S. V. Kik, G. J. Weverling, R. Dilan, S. L. King, L. F. Maxfield, S. Clark, D. Ng'ang'a, K. L. Brandariz, P. Abbink, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29: 5203-5209
15. Casimiro, D. R., L. Chen, T. M. Fu, R. K. Evans, M. J. Caulfield, M. E. Davies, A. Tang, M. Chen, L. Huang, V. Harris, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77: 6305-6313
16. Barouch, D. H., M. G. Pau, J. H. H. V. Custers, W. Koudstaal, S. Kostense, M. J. E. Havenga, D. M. Truitt, S. M. Sumida, M. G. Kishko, J. C. Arthur, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172: 6290-6297
17. Lindsay, R. W. B., P. A. Darrah, K. M. Quinn, U. Wille-Reece, L. M. Mattei, A. Iwasaki, S. P. Kasturi, B. Pulendran, J. G. D. Gall, A. G. Spies, and R. A. Seder. 2010. CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J. Immunol. 185: 1513-1521
18. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al; Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-ofconcept trial. Lancet 372: 1881-1893
19. Duerr, A., Y. Huang, S. Buchbinder, R. W. Coombs, J. Sanchez, C. del Rio, M. Casapia, S. Santiago, P. Gilbert, L. Corey, and M. N. Robertson; Step/HVTN 504 Study Team. 2012. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study). J. Infect. Dis. 206: 258-266
20. Cheng, C., L. Wang, J. G. D. Gall, M. Nason, R. M. Schwartz, M. J. McElrath, S. C. DeRosa, J. Hural, L. Corey, S. P. Buchbinder, and G. J. Nabel. 2012. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. PLoS ONE 7: e33969
21. Vogels, R., D. Zuijdgeest, R. van Rijnsoever, E. Hartkoorn, I. Damen, M. P. de Béthune, S. Kostense, G. Penders, N. Helmus, W. Koudstaal, et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77: 8263-8271
22. Kahl, C. A., J. Bonnell, S. Hiriyanna, M. Fultz, C. Nyberg-Hoffman, P. Chen, C. R. King, and J. G. D. Gall. 2010. Potent immune responses and in vitro proinflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28. Vaccine 28: 5691-5702
23. Farina, S. F., G. P. Gao, Z. Q. Xiang, J. J. Rux, R. M. Burnett, M. R. Alvira, J. Marsh, H. C. Ertl, and J. M. Wilson. 2001. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75: 11603-11613
24. Xiang, Z., G. Gao, A. Reyes-Sandoval, C. J. Cohen, Y. Li, J. M. Bergelson, J. M. Wilson, and H. C. J. Ertl. 2002. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76: 2667-2675
25. Peruzzi, D., S. Dharmapuri, A. Cirillo, B. E. Bruni, A. Nicosia, R. Cortese, S. Colloca, G. Ciliberto, N. La Monica, and L. Aurisicchio. 2009. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 27: 1293-1300
26. Colloca, S., E. Barnes, A. Folgori, V. Ammendola, S. Capone, A. Cirillo, L. Siani, M. Naddeo, F. Grazioli, M. L. Esposito,, et al 2012. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl. Med. 4: 115ra2
27. Seto, D., J. Chodosh, J. R. Brister, and M. S. Jones; Members of the Adenovirus Research Community. 2011. Using the whole-genome sequence to characterize and name human adenoviruses. J. Virol. 85: 5701-5702
28. Matsushima, Y., H. Shimizu, A. Kano, E. Nakajima, Y. Ishimaru, S. K. Dey, Y. Watanabe, F. Adachi, K. Suzuki, K. Mitani, et al. 2012. Novel human adenovirus strain, Bangladesh. Emerg. Infect. Dis. 18: 846-848
29. Xiang, Z. Q., Y. Yang, J. M.Wilson, and H. C. Ertl. 1996. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219: 220-227
30. Pinto, A. R., J. C. Fitzgerald, W. Giles-Davis, G. P. Gao, J. M. Wilson, and H. C. J. Ertl. 2003. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J. Immunol. 171: 6774-6779
31. Fitzgerald, J. C., G. P. Gao, A. Reyes-Sandoval, G. N. Pavlakis, Z. Q. Xiang, A. P. Wlazlo, W. Giles-Davis, J. M. Wilson, and H. C. J. Ertl. 2003. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170: 1416-1422
32. Barnes, E., A. Folgori, S. Capone, L. Swadling, S. Aston, A. Kurioka, J. Meyer, R. Huddart, K. Smith, R. Townsend, et al 2012. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci. Transl. Med. 4: 115ra1
33. Xiang, Z., Y. Li, A. Cun, W. Yang, S. Ellenberg, W. M. Switzer, M. L. Kalish, and H. C. J. Ertl. 2006. Chimpanzee adenovirus antibodies in humans, sub- Saharan Africa. Emerg. Infect. Dis. 12: 1596-1599
34. Sprangers, M. C., W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. E. Havenga, and S. Kostense. 2003. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J. Clin. Microbiol. 41: 5046-5052
35. McVey, D., M. Zuber, D. Ettyreddy, C. D. Reiter, D. E. Brough, G. J. Nabel, C. R. King, and J. G. D. Gall. 2010. Characterization of human adenovirus 35 and derivation of complex vectors. Virol. J. 7: 276
36. Honda, M., R. Wang, W. P. Kong, M. Kanekiyo, W. Akahata, L. Xu, K. Matsuo, K. Natarajan, H. Robinson, T. E. Asher, et al. 2009. Different vaccine vectors delivering the same antigen elicit CD8+ T cell responses with distinct clonotype and epitope specificity. J. Immunol. 183: 2425-2434
37. Liu, J., B. A. Ewald, D. M. Lynch, A. Nanda, S. M. Sumida, and D. H. Barouch. 2006. Modulation of DNA vaccine-elicited CD8+ T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80: 11991-11997
38. Wiesel, M., and A. Oxenius. 2012. From crucial to negligible: functional CD8+ T-cell responses and their dependence on CD4+ T-cell help. Eur. J. Immunol. 42: 1080-1088
39. Williams, M. A., B. J. Holmes, J. C. Sun, and M. J. Bevan. 2006. Developing and maintaining protective CD8+ memory T cells. Immunol. Rev. 211: 146-153
40. Yang, T. C., J. Millar, T. Groves,W. Zhou, N. Grinshtein, R. Parsons, C. Evelegh, Z. Xing, Y. Wan, and J. Bramson. 2007. On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol. Ther. 15: 997-1006
41. La Gruta, N. L., S. J. Turner, and P. C. Doherty. 2004. Hierarchies in cytokine expression profiles for acute and resolving influenza virus-specific CD8+ T cell responses: correlation of cytokine profile and TCR avidity. J. Immunol. 172: 5553-5560
42. Betts, M. R., M. C. Nason, S. M. West, S. C. De Rosa, S. A. Migueles, J. Abraham, M. M. Lederman, J. M. Benito, P. A. Goepfert, M. Connors, et al. 2006. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789
43. Darrah, P. A., D. T. Patel, P. M. De Luca, R. W. B. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13: 843-850
44. Kaech, S. M., J. T. Tan, E. J. Wherry, B. T. Konieczny, C. D. Surh, and R. Ahmed. 2003. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4: 1191-1198
45. Joshi, N. S., W. Cui, A. Chandele, H. K. Lee, D. R. Urso, J. Hagman, L. Gapin, and S. M. Kaech. 2007. Inflammation directs memory precursor and short-lived effector CD8+ T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295
46. Belyakov, I. M., P. Earl, A. Dzutsev, V. A. Kuznetsov, M. Lemon, L. S. Wyatt, J. T. Snyder, J. D. Ahlers, G. Franchini, B. Moss, and J. A. Berzofsky. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. USA 100: 9458-9463
47. Wyatt, L. S., P. L. Earl, L. A. Eller, and B. Moss. 2004. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl. Acad. Sci. USA 101: 4590-4595
48. Trumpfheller, C., J. S. Finke, C. B. López, T. M. Moran, B. Moltedo, H. Soares, Y. Huang, S. J. Schlesinger, C. G. Park, M. C. Nussenzweig, et al. 2006. Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J. Exp. Med. 203: 607-617
49. Vezys, V., A. Yates, K. A. Casey, G. Lanier, R. Ahmed, R. Antia, and D. Masopust. 2009. Memory CD8 T-cell compartment grows in size with immunological experience. Nature 457: 196-199
50. Tatsis, N., S. W. Lin, K. Harris-McCoy, D. A. Garber, M. B. Feinberg, and H. C. J. Ertl. 2007. Multiple immunizations with adenovirus and MVA vectors improve CD8+ T cell functionality and mucosal homing. Virology 367: 156-167
51. Casimiro, D. R., A. J. Bett, T. M. Fu, M. E. Davies, A. Tang, K. A. Wilson, M. Chen, R. Long, T. McKelvey, M. Chastain, et al. 2004. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J. Virol. 78: 11434-11438
52. Jiang, G., M. Shi, S. Conteh, N. Richie, G. Banania, H. Geneshan, A. Valencia, P. Singh, J. Aguiar, K. Limbach, et al. 2009. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: comparison of heterologous prime boost strategies. PLoS ONE 4: e6559
53. Reyes-Sandoval, A., T. Berthoud, N. Alder, L. Siani, S. C. Gilbert, A. Nicosia, S. Colloca, R. Cortese, and A. V. S. Hill. 2010. Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses. Infect. Immun. 78: 145-153
54. Barouch, D. H., J. Liu, H. Li, L. F. Maxfield, P. Abbink, D. M. Lynch, M. J. Iampietro, A. SanMiguel, M. S. Seaman, G. Ferrari, et al. 2012. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482: 89-93
55. Koblin, B. A., M. Casapia, C. Morgan, L. Qin, Z. M. Wang, O. D. Defawe, L. Baden, P. Goepfert, G. D. Tomaras, D. C. Montefiori, et al; NIAID HIV Vaccine Trials Network. 2011. Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial. PLoS ONE 6: e24517
56. Koup, R. A., M. Roederer, L. Lamoreaux, J. Fischer, L. Novik, M. C. Nason, B. D. Larkin, M. E. Enama, J. E. Ledgerwood, R. T. Bailer, et al; VRC 009 Study Team; VRC 010 Study Team. 2010. Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 5: e9015
57. Churchyard, G. J., C. Morgan, E. Adams, J. Hural, B. S. Graham, Z. Moodie, D. Grove, G. Gray, L. G. Bekker, M. J. McElrath, et al; NIAID HIV Vaccine Trials Network. 2011. A phase IIA randomized clinical trial of a multiclade HIV- 1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS ONE 6: e21225
58. Gaggar, A., D. M. Shayakhmetov, and A. Lieber. 2003. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9: 1408-1412
59. Zhang, Y., and J. M. Bergelson. 2005. Adenovirus receptors. J. Virol. 79: 12125-12131
60. Johnson, M. J., C. Petrovas, T. Yamamoto, R. W. B. Lindsay, K. Loré, J. G. D. Gall, E. Gostick, F. Lefebvre, M. J. Cameron, D. A. Price, et al. 2012. Type I IFN induced by adenovirus serotypes 28 and 35 has multiple effects on T cell immunogenicity. J. Immunol. 188: 6109-6118
61. Schmidt, N. W., N. S. Butler, V. P. Badovinac, and J. T. Harty. 2010. Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog. 6: e1000998
62. Schmidt, N. W., R. L. Podyminogin, N. S. Butler, V. P. Badovinac, B. J. Tucker, K. S. Bahjat, P. Lauer, A. Reyes-Sandoval, C. L. Hutchings, A. C. Moore, et al. 2008. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. USA 105: 14017-14022
63. Hansen, S. G., J. C. Ford, M. S. Lewis, A. B. Ventura, C. M. Hughes, L. Coyne- Johnson, N. Whizin, K. Oswald, R. Shoemaker, T. Swanson, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473: 523-527
64. Yang, T. C., J. Millar, T. Groves, N. Grinshtein, R. Parsons, S. Takenaka, Y. Wan, and J. L. Bramson. 2006. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J. Immunol. 176: 200-210
65. Zajac, A. J., J. N. Blattman, K. Murali-Krishna, D. J. Sourdive, M. Suresh, J. D. Altman, and R. Ahmed. 1998. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188: 2205-2213
66. Wherry, E. J., J. N. Blattman, K. Murali-Krishna, R. van der Most, and R. Ahmed. 2003. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77: 4911-4927
67. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687
68. Blackburn, S. D., H. Shin, W. N. Haining, T. Zou, C. J. Workman, A. Polley, M. R. Betts, G. J. Freeman, D. A. A. Vignali, and E. J. Wherry. 2009. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10: 29-37
69. Bengsch, B., B. Seigel, M. Ruhl, J. Timm, M. Kuntz, H. E. Blum, H. Pircher, and R. Thimme. 2010. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8+ T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog. 6: e1000947
70. Tatsis, N., J. C. Fitzgerald, A. Reyes-Sandoval, K. C. Harris-McCoy, S. E. Hensley, D. Zhou, S. W. Lin, A. Bian, Z. Q. Xiang, A. Iparraguirre, et al. 2007. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110: 1916-1923
71. Finn, J. D., J. Bassett, J. B. Millar, N. Grinshtein, T. C. Yang, R. Parsons, C. Evelegh, Y. Wan, R. J. Parks, and J. L. Bramson. 2009. Persistence of transgene expression influences CD8+ T-cell expansion and maintenance following immunization with recombinant adenovirus. J. Virol. 83: 12027-12036
72. Sullivan, N. J., L. Hensley, C. Asiedu, T. W. Geisbert, D. Stanley, J. Johnson, A. Honko, G. Olinger, M. Bailey, J. B. Geisbert, et al. 2011. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17: 1128-1131
73. Geisbert, T. W., M. Bailey, L. Hensley, C. Asiedu, J. Geisbert, D. Stanley, A. Honko, J. Johnson, S. Mulangu, M. G. Pau, et al. 2011. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J. Virol. 85: 4222-4233
74. Prlic, M., J. A. Sacks, and M. J. Bevan. 2012. Dissociating markers of senescence and protective ability in memory T cells. PLoS ONE 7: e32576
75. Wiesel, M., J. Crouse, G. Bedenikovic, A. Sutherland, N. Joller, and A. Oxenius. 2012. Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. Eur. J. Immunol. 42: 320-329
76. Obar, J. J., E. R. Jellison, B. S. Sheridan, D. A. Blair, Q. M. Pham, J. M. Zickovich, and L. Lefrancois. 2011. Pathogen-induced inflammatory environment controls effector and memory CD8+ T cell differentiation. J. Immunol. 187: 4967-4978
77. Ahmed, R., A. Salmi, L. D. Butler, J. M. Chiller, and M. B. Oldstone. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice: role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160: 521-540
78. Thimme, R., V. Appay, M. Koschella, E. Panther, E. Roth, A. D. Hislop, A. B. Rickinson, S. L. Rowland-Jones, H. E. Blum, and H. Pircher. 2005. Increased expression of the NK cell receptor KLRG1 by virus-specific CD8 T cells during persistent antigen stimulation. J. Virol. 79: 12112-12116
79. Wirth, T. C., M. D. Martin, G. Starbeck-Miller, J. T. Harty, and V. P. Badovinac. 2011. Secondary CD8+ T-cell responses are controlled by systemic inflammation. Eur. J. Immunol. 41: 1321-1333
80. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, et al; MOPH-TAVEG Investigators. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220
81. Jaoko, W., E. Karita, K. Kayitenkore, G. Omosa-Manyonyi, S. Allen, S. Than, E. M. Adams, B. S. Graham, R. A. Koup, R. T. Bailer, et al. 2010. Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa. PLoS ONE 5: e12873
82. Barratt-Boyes, S. M., A. C. Soloff, W. Gao, E. Nwanegbo, X. Liu, P. A. Rajakumar, K. N. Brown, P. D. Robbins, M. Murphey-Corb, R. D. Day, and A. Gambotto. 2006. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors. J. Gen. Virol. 87: 139-149
83. Loré, K., W. C. Adams, M. J. E. Havenga, M. L. Precopio, L. Holterman, J. Goudsmit, and R. A. Koup. 2007. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J. Immunol. 179: 1721-1729